Core Points - The announcement from Zhejiang Haizheng Biomaterials Co., Ltd. indicates that its major shareholder, Sinopec Capital, has reduced its stake in the company [2] - Sinopec Capital held 12,814,894 shares, representing 6.32% of the total share capital before the reduction [2] - As of November 11, 2025, Sinopec Capital has sold 2,026,700 shares through centralized bidding, which is 1% of the total share capital [2] - After the completion of the reduction plan, Sinopec Capital now holds 10,788,194 shares, accounting for 5.32% of the total share capital [2]

Group 1 - The core point of the article is that Sinopec Capital has completed a share reduction plan for Haizheng Biomaterials, reducing its stake to 5.32% of the total shares outstanding [1] - As of November 11, 2025, Sinopec Capital has reduced its holdings by 2,026,700 shares, which represents 1% of the total share capital of Haizheng Biomaterials [1] - Following the reduction, Sinopec Capital now holds 10,788,194 shares in Haizheng Biomaterials [1] Group 2 - Haizheng Biomaterials reported that its revenue composition for the year 2024 is heavily weighted towards the fiber manufacturing industry, accounting for 98.77% of total revenue [1] - The company's other business segments contribute only 1.23% to its overall revenue [1] - As of the latest report, Haizheng Biomaterials has a market capitalization of 2.7 billion yuan [2]

证券代码：688203 证券简称：海正生材 公告编号：2025-56 浙江海正生物材料股份有限公司 股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 浙江海正生物材料股份有限公司（以下简称"公司"或"海正生材"）持股 5%以上股东中国石化集团资本有限公司（以下简称"中石化资本"）持有公司股 份 12,814,894 股，占公司总股本的 6.32%。上述股份为公司首次公开发行前取 得的股份，并已于 2024 年 2 月 19 日起上市流通。 减持计划的实施结果情况 | 股东名称 | 中国石化集团资本有限公司 | | | --- | --- | --- | | 股东身份 | 控股股东、实控人及一致行动人 | □是 √否 | | | 直接持股 5%以上股东 | √是 □否 | | | 董事、监事和高级管理人员 | □是 √否 | | | 其他：/ | | | 持股数量 | 12,814,894股 | | | 持股比例 | 6.32% | | | 当前持股股份来 ...

Group 1 - The core point of the article is that the company, Hai Zheng Sheng Cai (688203.SH), has completed a share reduction plan initiated by its shareholder, Sinopec Capital [1] - As of November 11, 2025, Sinopec Capital has reduced its holdings by a total of 2.0267 million shares, which represents 1% of the company's total share capital [1]

Core Viewpoint - Sinopec Capital, a shareholder holding more than 5% of the shares, has reduced its stake in Haizheng Biomaterials due to funding needs for business development, completing the reduction plan as of November 11 [1] Group 1: Shareholder Reduction - Sinopec Capital originally held 12,814,894 shares, accounting for 6.32% of the total share capital [1] - The reduction plan was disclosed on September 26, 2025, allowing for a maximum reduction of 2,026,700 shares, which is up to 1% of the total share capital [1] - As of November 11, Sinopec Capital has completed the reduction, selling 2,026,700 shares for a total amount of 26.73 million yuan, reducing its holding to 10,788,194 shares, which is 5.32% of the total share capital [1]

Group 1 - The company Zhejiang Haizheng Biomaterials Co., Ltd. has approved a share repurchase plan to buy back its A-shares using its own funds, with a maximum price of RMB 12.00 per share and a total repurchase amount between RMB 20 million and RMB 30 million [2] - The repurchase period is set for a maximum of 12 months from the date of board approval, which is August 28, 2024 [2] - As of October 31, 2025, the company has repurchased a total of 1,900,000 shares, accounting for 0.937% of the total share capital, with a total expenditure of approximately RMB 20.49 million [2][5] Group 2 - The company adjusted the source of repurchase funds from "own funds" to include "own funds and special loans for stock repurchase" as of March 11, 2025 [2] - The maximum repurchase price was later increased to RMB 17.00 per share, and the repurchase period was extended by 6 months to February 27, 2026 [2] - The highest and lowest prices for the repurchased shares were RMB 15.98 and RMB 7.76 per share, respectively [2] Group 3 - On November 3, 2025, the company received a notice from its shareholder, Sinopec Group Capital Co., Ltd., regarding a reduction in shareholding [6] - Sinopec Group Capital reduced its holdings by 783,484 shares, bringing its total shares down to 12,031,410, which is 5.94% of the total share capital [6][7] - This reduction is part of a previously disclosed share reduction plan and will not affect the company's controlling shareholder or its governance structure [7][8]

证券日报网讯 11月3日晚间，海正生材发布公告称，2025年10月，公司未回购股份。 （文章来源：证券日报） ...

浙江海正生物材料股份有限公司 关于股份回购进展公告 证券代码：688203 证券简称：海正生材 公告编号：2025-55 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/8/29 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 日~2026 月 2025 28 2 | 8 | 月 | 年 | 27 | 日 | | 预计回购金额 | 2,000万元~3,000万元 | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | | □为维护公司价值及股东权益 | | | | | | | 累计已回购股数 | 1,900,000股 | | | | | | | 累计已回购股数占总股本比例 | 0.937% | | | | | | | 累计已回购金额 | 20,494,429.47元 | | | | | | | 实际回 ...

证券代码：688203 证券简称：海正生材 公告编号：2025-54 浙江海正生物材料股份有限公司 关于持股 5%以上股东权益变动触及 1%刻度的提示性 公告 股东中国石化集团资本有限公司保证向本公司提供的信息真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 2.信息披露义务人信息 信息披露义务人名称 投资者身份 统一社会信用代码 中国石化集团资本有 限公司 □ 控股股东/实控人 □ 控股股东/实控人的一致 行动人 √ 其他直接持股股东 √ 91130629MA0CHPU501_ □ 不适用 1.身份类别 | | □控股股东/实际控制人及其一致行动人 √其他 | | --- | --- | | | 5%以上大股东及其一致行动人 | | 投资者及其一致行动人的身份 | □合并口径第一大股东及其一致行动人（仅适用 | | | 于无控股股东、实际控制人） | | | □其他_____/_________（请注明） | 重要内容提示： 权益变动方向 比例增加□ 比例减少√ 权益变动前合计比例 6.32% 权益变动后合计比例 5.94% 本次变动是否违反已作出的承 诺、意向、计划 是□ 否√ 是否触发强制要约收 ...

海正生材公告称，2025年10月28日至10月31日，股东中国石化集团资本有限公司通过集中竞价交易减持 78.35万股。减持后，其持股数量由1281.49万股降至1203.14万股，持股比例由6.32%降至5.94%，权益变 动触及1%整数倍。本次减持是履行此前披露的计划，且计划尚未实施完毕，不会导致公司控股股东及 实控人变化，也不涉及披露简式权益变动报告书。 ...